Table 2.

Dosimetric differences used for plan evaluation in RAPID and NSABP B‐39 clinical trials.

OAR	RAPID Trial	NASBP B‐39/RTOG 0413
Ipsilateral breast	$\mathrm{V}95\%\le 35$ (up to 37%)	$\mathrm{V}100\%\le 35\%$
Ipsilateral lung	$\mathrm{V}10\%\le 20\%$ (up to 23%) $\mathrm{V}30\%\le 10\%$ (up to 13%)	V30% $<15\%$
Heart
Right‐sided	D5% $<5\%$	V5% $<5\%$
Left‐sided	5% D5% $<15\%$	V5% $<40\%$
Target (DEV)	$\mathrm{V}95\%\ge 95\%$	$\mathrm{V}90\%\ge 90\%$ ${\mathrm{D}}_{max}$ ≤ 120%